Barbara Alicja Jereczek-Fossa
Overview
Explore the profile of Barbara Alicja Jereczek-Fossa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
302
Citations
2478
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Milano M, Valenza C, Ferrari A, Gandini S, Trapani D, Santoro C, et al.
Eur J Cancer
. 2024 Dec;
215:115164.
PMID: 39662096
Background: About 15-20 % of patients with metastatic breast cancer (mBC) can experience oligoprogressive disease (OPD) in ≤ 5 sites of disease. Patients with OPD may benefit from metastasis-directed stereotactic...
12.
Muller V, Bachelot T, Curigliano G, de Azambuja E, Furtner J, Gempt J, et al.
Cancer Treat Rev
. 2024 Nov;
132:102860.
PMID: 39612906
Background: Patients with HER2-positive breast cancer have a significant risk of developing brain metastases (BrM), which have detrimental effects on survival outcomes and quality of life. Although there are several...
13.
Lancia A, Alitto A, Pappagallo G, Ciurlia E, Francolini G, DAngelillo R, et al.
Pract Radiat Oncol
. 2024 Nov;
PMID: 39490734
Purpose: Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of Radiotherapy and Clinical Oncology aimed to...
14.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...
15.
Bilski M, Konat-Baska K, Mastroleo F, Hoskin P, Jereczek-Fossa B, Marvaso G, et al.
Clin Transl Radiat Oncol
. 2024 Sep;
49:100845.
PMID: 39290455
Bone metastases (BMs) are the most common cause of cancer-related pain and radiation therapy plays a key role in treating pain caused by it. The half-body irradiation (HBI) is a...
16.
Volpe S, Mastroleo F, Vincini M, Zaffaroni M, Porazzi A, Damiani E, et al.
Crit Rev Oncol Hematol
. 2024 Sep;
204:104500.
PMID: 39245297
Purpose: To focus on the ecological footprint of radiotherapy (RT), on opportunities for sustainable practices, on future research directions. Methods: Different databases were interrogated using the following terms: Carbon Footprint,...
17.
Isaksson L, Mastroleo F, Vincini M, Marvaso G, Zaffaroni M, Gola M, et al.
Crit Rev Oncol Hematol
. 2024 Sep;
204:104485.
PMID: 39233128
Artificial intelligence (AI) has made a tremendous impact in the space of healthcare, and proton therapy is not an exception. Proton therapy has witnessed growing popularity in oncology over recent...
18.
Morelli L, Paganelli C, Marvaso G, Parrella G, Annunziata S, Vicini M, et al.
Med Phys
. 2024 Aug;
51(11):8096-8107.
PMID: 39172115
Background: Prostate cancer (PCa) is a highly heterogeneous disease, making tailored treatment approaches challenging. Magnetic resonance imaging (MRI), notably diffusion-weighted imaging (DWI) and the derived Apparent Diffusion Coefficient (ADC) maps,...
19.
Kuncman L, Pajdzinski M, Smolka K, Bilski M, Socha J, Stando R, et al.
Front Immunol
. 2024 Aug;
15:1426635.
PMID: 39148729
Introduction: Radiation induced lymphopenia (RIL) deteriorate survival and diminishes the benefit of immune checkpoint inhibitors in combined treatment of lung cancer. Given the inconsistent data across various studies on the...
20.
Tagliabue M, Ruju F, Mossinelli C, Gaeta A, Raimondi S, Volpe S, et al.
Radiol Med
. 2024 Aug;
129(9):1369-1381.
PMID: 39096355
Purpose: Radiomics is an emerging field that utilizes quantitative features extracted from medical images to predict clinically meaningful outcomes. Validating findings is crucial to assess radiomics applicability. We aimed to...